BioSpace News Archive

Amarin Tangles with Activist Investor (Updated)

Amarin Corporation wrestled with activist investor Sarissa Capital Management as the latter tried to replace Amarin’s current board of directors with its representatives.

January 11, 2023
·
1 min read
·
Tristan Manalac
Drug Development

Alto’s Biomarker-Based Depression Trial Bears Positive Data

Alto reported positive data from a first-of-its-kind Phase IIb trial of major depressive disorder candidate ALTO-100.

January 11, 2023
·
3 min read
·
Heather McKenzie
Drug Development

Lilly Gears Up for ‘Unprecedented Year,’ Touts Promising Pipeline

Following a banner year marked by the approval and launch of its diabetes drug Mounjaro, Eli Lilly revealed at the 41st J.P. Morgan Healthcare Conference that it was preparing for another big year.

January 11, 2023
·
2 min read
·
Tristan Manalac
Business

AbbVie Braves Humira LOE, Remains Confident in Long-Term Growth

In a fireside chat at the 41st J.P. Morgan Healthcare Conference in San Francisco, CEO Rick Gonzalez said AbbVie is well-positioned for continued growth.

January 11, 2023
·
2 min read
·
Tristan Manalac
FDA

JPM Day 3: Highlights

Stay on top of what’s happening at JPM. BioSpace is covering all the key announcements all week.

January 11, 2023
·
5 min read
·
Editorial Staff
Career Advice

Is Relocation Really Worth It? Weighing The Pros and Cons of Biopharma Hot Spots

Discover the benefits and challenges of relocating to a biopharma hot spot and find out the most important factors to consider when making your decision.

January 11, 2023
·
3 min read
·
Rosemary Scott
Drug Development

BioXcel Spinout Posts Promising Results in Rare Prostate Cancer

BioXcel Therapeutics subsidiary OnkosXcel announced positive Phase II results in patients with small cell neuroendocrine metastatic castration-resistant (SCNC) prostate cancer.

January 11, 2023
·
2 min read
·
Kate Goodwin
Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing

Valo Therapeutics Oy announced it has selected Exothera S.A., a full-service Contract Development and Manufacturing Organization specialized in gene therapy, vaccines, and oncolytic viruses, to develop a large-scale manufacturing process for clinical development of its oncolytic adenovirus, VALO-D102.

January 11, 2023
·
3 min read
Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 February 2023

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, invites the holders of securities issued by the Company to attend the Extraordinary General Meeting of Shareholders on Friday, 10 February 2023.

January 11, 2023
·
5 min read
Biotech Bay

S2 Genomics Announces Distribution Agreement with Bonsailab to Serve Iberian Peninsula

Singulator™ 100 and Singulator™ 200 Systems and components to be available through local distributor in Spain and Portugal.

January 11, 2023
·
2 min read